EMPA-REG OUTCOME: Analysis in Women with T2DM and CVD

May 18, 2018
Veronica Hackenthal, MD

A recent trial found that empagliflozin can reduce the risk of cardiovascular deaths in type 2 diabetes patients; are results similar in men and women?